Evidence-based tactics--supported by the pharma industry--are a targeted goal
NEHI (Cambridge, MA), a public-policy institute, has tagged improved medication adherence as a national priority for several years now, having estimated the cost to the healthcare system from poor adherence to be $290 billion in 2009. A newly published report, Six Priorities for Action to Support Patient Medication Adherence, reiterates goals around which industry, providers, payers and government can unite:
A 2012 study, from Capgemini, estimated a loss of over $188 billion in lost pharma revenue from poor adherence—which is roughly two-thirds the value of all US pharma sales. And there’s the rub: historically, providers and payers have looked on pharma’s input in adherence as being self-serving. But that attitude is changing, in part because of the renewed forcus of the Affordable Care Act on outcomes- or value-based medical care.
“Historically we’ve treated medicines as a category of medical expenditure that needs to be managed, not as an asset that can be optimized to yield optimal outcomes at an optimal total cost of care,” says Tom Hubbard, VP of policy research at NEHI. “That’s changing now,” he says, noting that a change in Congressional Budget Office analysis occurred late last year, enabling CBO to include the health cost savings of medicine use in budget estimates—and not just the cost of those medicines.
Physicians Interactive (Reading, MA), one of many marketing services companies for pharma, is executing on the evidence-based tactics that NEHI highlights. By including predictive analytics (of how patients will comply with treatment regimens) along with educational and financial support (in the form of coupons and other patient assistance) in the workflow of physicians, pharma support of adherence can become an asset to providers and payers, says Gene Guselli, president of global operations at the firm. In its most refined form (which Guselli says is being put into use at some provider sites), the patient support tools are integrated into the electronic health record (EHR) systems at the site, giving physicians timely reports on refills and other adherence measures. “Physicians can move from prescribing drugs to prescribing adherence,” he boasts.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.